Abacus Medicine Pharma Services and AddMedica sign partnership agreement for the distribution of Siklos® in Benelux
Abacus Medicine Pharma Services (AMPS) and AddMedica are proud to announce the signing of a partnership agreement for the marketing and distribution of Siklos® in Benelux.
Siklos® 100mg and 1000mg film-coated tablets are indicated for the treatment of adults, adolescents and children over two years of age who have sickle-cell syndrome. Siklos® is used to prevent recurrent, painful vaso-occlusive crises that happen when blood vessels become blocked by the abnormal red blood cells, restricting the flow of blood to an organ.
Simon Estcourt, Managing Director of Abacus Medicine Pharma Services explains:
“This partnership agreement between Abacus Medicine Pharma Services and AddMedica is a fantastic opportunity as it unlocks the potential of Siklos® in the Benelux countries. We are delighted that this distribution agreement will make this treatment option available to patients in Belgium, The Netherlands and Luxembourg.”